Out-of-hospital cardiac arrest (OHCA) is a global public health problem. 1 In patients who are resuscitated from OHCA, hypoxic brain injury is an important cause of morbidity and mortality. [2][3][4] Targeted temperature management (TTM) ameliorates hypoxic brain damage after OHCA. 5,6 Currently, TTM is the standard treatment for postresuscitated patients. However, it is unclear whether the cooling time (CT) in TTM is a time-sensitive issue. Several studies have shown that early achievement of the target temperature is associated with a favorable neurological prognosis. 7-10 However, other studies have found that reaching the target temperature too quickly increases mortality. [11][12][13] In a recent study comparing targeted hypothermia at 33°C and targeted normothermia at 37.5°C, there was no significant difference

Acute pancreatitis is an uncommon side effect of pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) combination therapy. In South Korea, There is a no report of acute pancreatitis associated PEG-IFN α-2b plus RBV combination therapy. Here, acute pancreatitis associated with PEG-IFN α-2b plus RBV treatment is described in two patients with chronic hepatitis C. We started on weekly subcutaneous injection of PEG-IFN α-2b plus daily RBV. During this therapy, acute pancreatitis occurred in these patients without other causes of acute pancreatitis. We thought that the cause of acute pancreatitis in these patients was PEG-IFN α-2b and RBV. We stopped the treatment of PEG-IFN α-2b and RBV, and patients were improved.

No abstract